ImmunityBio Covid-19 Vaccine to Be Trialed in South Africa

(Bloomberg) -- University of Cape Town researchers will oversee a phase one clinical trial of a Covid-19 vaccine developed by ImmunityBio Inc. and manufactured by NantKwest Inc.

The vaccine is known as hAd5 T-cell and the trial will start this month, the university said in a statement dated Monday. In addition to the spike protein the shot targets the nucleocapsid protein, which is less prone to mutations.

©2021 Bloomberg L.P.